Cogent Biosciences, Inc. (COGT) Stock Price & Analysis
Cogent Biosciences, Inc. (COGT) closed at USD 29.51 on Thursday, October 15, 2026, up 4.83% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 28.15; the Oct 15, 2026 session ranged USD 28.33–29.78 on volume of 3,037,591 shares. Market capitalization is $5.12B, with a 52-week range of USD 13.78–43.73 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/COGT.md
Key facts (COGT)
- Analysts: Buy (mean 1.92 on a 1–5 scale) (12 analysts), mean target USD 55.82 (range 45–62).
- Total return with dividends: 1Y +80.4% vs S&P 500 +18.1%; 5Y +219.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.55, revenue estimate $0K.
Analysts (COGT)
Consensus Buy (mean 1.92 on a 1–5 scale), 12 analysts; mean target USD 55.82 (low 45, high 62).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Wedbush | Reiterated | Outperform | $55 |
| 2026-09-15 | HC Wainwright & Co. | Reiterated | Buy | $55 |
| 2026-08-17 | Piper Sandler | Target raised | Overweight | $52 → $55 |
| 2026-08-12 | Guggenheim | Target raised | Buy | $45 → $52 |
Total return (dividends reinvested) (COGT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +80.4% | +219.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +80.7% | +26.1% |
| Volatility (annualized) | 91.2% | 85.2% |
| Max drawdown | -34.4% (Aug 2026→Oct 2026) | -74.0% (Sep 2022→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 29.51 |
|---|---|
| Change | ▲ 4.83% (up) |
| Previous Close | USD 28.15 |
| Open | USD 28.33 |
| Day Range | USD 28.33 – 29.78 |
| 52-Week Range | USD 13.78 – 43.73 |
| Volume | 3,037,591 shares |
| Market Cap | $5.12B |
| Exchange | NMS |
Technical Analysis (COGT)
Nexqual's technical model rates COGT "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.43 (neutral) |
| vs SMA50 | Below (USD 34.09) |
| MACD | -1.4 (negative) |
Analyst Ratings (COGT)
Wall Street analysts rate COGT "Buy" based on 12 analysts, with a mean price target of USD 55.82 (range USD 45–62), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 55.82 |
| High Target | USD 62 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (COGT)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.52 vs est -0.56 ▲ beat |
| 2026-03-31 | USD -0.53 vs est -0.54 ▲ beat |
| 2025-12-31 | USD -0.56 vs est -0.51 ▼ miss |
| 2025-09-30 | USD -0.5 vs est -0.52 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (COGT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -109.74% |
| Debt / Equity | 0.46 |
| Current Ratio | 13.57 |
| Total Cash | $792.30M |
| Total Debt | $244.26M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (COGT)
Nexqual rates Cogent Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $792M cash vs $244M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$264M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -110%, ROA -43.8% |
Ownership (COGT)
| Insider Ownership | +0.42% |
|---|---|
| Institutional Ownership | +115.22% |
| Shares Outstanding | 173.52M |
| Float | 172.56M |
| Short % of Float | +11.28% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (COGT)
Cogent Biosciences, Inc. is led by Andrew R. Robbins (age 49), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | Andrew R. Robbins (age 49) |
|---|---|
| CFO & Principal Accounting Officer | John L. Green C.A. (age 45) |
| Chief Scientific Officer | John Edward Robinson (age 51) |
| Chief Technology Officer | Brad Barnett |
| Senior Director of Investor Relations | Christi Waarich |
Major Backers & Investors (COGT)
Notable institutional backers of Cogent Biosciences, Inc. include FMR, LLC, Fidelity, Jupiter Topco LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.8% |
| Fidelity | 4.66% |
| Jupiter Topco LLC | 3.82% |
| Fairmount Funds Management LLC | 3.17% |
| Deerfield Management Company, L.P | 2.88% |
| TCG Crossover Management, LLC | 2.8% |
| Price (T.Rowe) Associates Inc | 2.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.53% |
| BlackRock | 12.45% |
| State Street | 6.26% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt